Skip to main content
. 2022 Apr 6;8(14):eabl8054. doi: 10.1126/sciadv.abl8054

Fig. 4. The CXCL12/CXCR4 axis mediates OPC migration through Rac1.

Fig. 4.

(A and B) μCT images and quantitative analysis of pathological new bone formation in PGIS mice at the age of 32 weeks after EHT1864 administration. Scale bars, 500 μm. n = 6 per group. (C) H&E staining, TB staining, immunohistochemical staining, and immunofluorescence staining of Sca1 in PGIS mice. Scale bars, 100 μm. n = 6 per group. (D and E) Quantitative analysis of Sca1 in (C). (F) μCT images of pathological new bone formation in hind paw of male DBA/1 mice at the age of 32 weeks after EHT1864 administration. Scale bar, 50 μm. n = 6 per group. (G) H&E staining, SOFG staining, immunohistochemical staining, and immunofluorescence staining of Prx1 in plantar surface of hind paw of male DBA/1 mice at the age of 32 weeks after EHT1864 administration. Scale bars, 50 μm. n = 6 per group. (H) Quantitative analysis of pathological new bone formation in (F). (I and J) Quantitative analysis of Prx1 in (G). Data are shown as means ± SEM. Student’s t test with Shapiro-Wilk test was used. EHT1864, Rac1 inhibitor.